Clinical Development Programs
The Astellas partnership includes a treatment for hypercholesterolemia (evolocumab), a treatment for osteoporosis (romosozumab) and a treatment for oncology (blinatumomab).
Co-developed Pipeline Medicines between Amgen Astellas BioPharma and Astellas Pharma
General Name
(Development Code) |
Lead Indication |
Mode of Action |
Development Stage |
| |
Overseas |
Japan |
| Evolocumab (AMG 145) |
Hypercholesterolemia |
Anti-PCSK-9 mAb |
Launch |
Launch |
| Romosozumab (AMG 785)1 |
Osteoporosis |
Anti-Sclerostin mAb |
Phase 3 |
Phase 3 |
| Blinatumomab (AMG 103) |
Acute Lymphoblastic
Leukemia (ALL) |
Anti-CD19 BiTE® |
Launch |
Phase 2 |
Pipeline Medicines by Amgen Astellas BioPharma
General Name
(Development Code) |
Lead Indication |
Mode of Action |
Development Stage |
| |
Overseas |
Japan |
| AMG 678 |
Malignant Melanoma |
Oncolytic Virus |
Launch |
Phase 1 |
| AMG 334 |
Migraine prevention |
Anti-CGRP Receptor
mAb |
Phase 3 |
Phase 2 |
| AMG 423 |
Chronic heart failure |
Cardiac myosin
activator |
Phase 2 |
Phase 2 |